Families affected by Duchenne muscular dystrophy (DMD) received encouraging news as Dyne Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for z-rostudirsen (formerly DYNE-251). The investigational therapy is being developed for people with Duchenne muscular dystrophy amenable to exon 51 skipping.
The FDA has also granted Priority Review, shortening the review timeline and setting a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027. If approved, Dyne expects to launch z-rostudirsen in the United States during the first quarter of 2027.
Table of Contents
What Is Z-Rostudirsen?
Z-rostudirsen (formerly known as DYNE-251) is an investigational exon skipping therapy designed for individuals with Duchenne muscular dystrophy caused by mutations that are amenable to exon 51 skipping.
The therapy uses Dyne Therapeutics’ proprietary FORCE™ platform, which is designed to improve delivery of therapeutic molecules directly into skeletal and cardiac muscle cells. By enhancing delivery to muscle tissue, the treatment aims to increase production of near-full-length dystrophin protein, which is essential for maintaining healthy muscle function.
Unlike traditional exon skipping therapies that may have limited muscle uptake, z-rostudirsen was specifically engineered to improve tissue delivery while maintaining a favorable safety profile.
Learn More: Mutations and Deletions Amenable to Exon 51 Skipping Therapies
FDA Accepts Biologics License Application
The FDA’s acceptance of the Biologics License Application (BLA) means the agency has determined that the application is sufficiently complete to begin its formal scientific review. Read More: Biologics License Application (BLA)
As part of this process:
- The FDA granted Priority Review, reducing the standard review period.
- The PDUFA target action date has been set for January 21, 2027.
- The application seeks Accelerated Approval based on dystrophin production as a surrogate endpoint.
If the FDA concludes that increased dystrophin production is reasonably likely to predict clinical benefit, z-rostudirsen could receive Accelerated Approval while additional studies continue to confirm long-term clinical outcomes.
Why Is Accelerated Approval Important?
Understanding the Accelerated Approval Pathway
Developing treatments for rare diseases such as Duchenne muscular dystrophy often takes many years.
To help patients gain earlier access to promising therapies, the FDA created the Accelerated Approval pathway. This regulatory pathway allows approval based on a surrogate endpoint that is reasonably likely to predict clinical benefit.
For Duchenne muscular dystrophy, dystrophin production has become one of the most important surrogate biomarkers evaluated by regulators.
Companies receiving Accelerated Approval are generally required to continue post-marketing studies to confirm that patients experience meaningful long-term clinical benefits.
Use Our Tool NOW: DMD/BMD Exon Analysis Tool
DELIVER Trial Results
The BLA submission is supported by results from the registrational expansion cohort of the Phase 1/2 DELIVER clinical trial.
According to Dyne Therapeutics, participants receiving z-rostudirsen once every four weeks demonstrated:
Significant Increase in Dystrophin
Patients experienced a robust and statistically significant increase in dystrophin production, supporting the primary biological objective of exon skipping therapy.
Improvements Across Multiple Functional Measures
Beyond laboratory findings, researchers also observed improvements across multiple clinical functional endpoints, suggesting that the increased dystrophin may translate into better physical performance.
Although additional long-term studies are still ongoing, these functional findings strengthen the overall evidence supporting the therapy.
Favorable Safety Profile
The company also reported a favorable safety profile, with treatment generally being well tolerated throughout the study period.
Safety remains one of the key considerations during the FDA review process.
Dyne Therapeutics Plans U.S. Launch in Early 2027
Assuming FDA approval is granted on schedule, Dyne Therapeutics expects to make z-rostudirsen commercially available in the United States during the first quarter of 2027.
Company President and CEO John Cox stated that the goal is to provide a therapy capable of delivering:
- Robust production of near-full-length dystrophin
- Broad delivery into relevant muscle tissues
- Functional improvement for people living with Duchenne muscular dystrophy
The company also acknowledged the important role played by patients, families, investigators, advocacy organizations, and the broader Duchenne community throughout the clinical development process.
Dyne’s Broader Duchenne Pipeline
Z-rostudirsen represents only one part of Dyne Therapeutics’ broader Duchenne muscular dystrophy development program.
The company is also advancing several additional investigational exon skipping therapies targeting other genetic mutations.
DYNE-253
Designed for patients amenable to exon 53 skipping.
DYNE-245
Designed for patients amenable to exon 45 skipping.
DYNE-244
Designed for patients amenable to exon 44 skipping.
DYNE-255
Designed for patients amenable to exon 55 skipping.
If successful, these programs could expand treatment options for a much larger proportion of individuals living with Duchenne muscular dystrophy.
What This Means for the Duchenne Community
The FDA’s acceptance of the BLA represents an important regulatory milestone rather than a final approval.
However, it demonstrates that:
- The FDA has begun its formal review of z-rostudirsen.
- Priority Review reflects the potential importance of the therapy.
- The application is supported by statistically significant dystrophin production data and encouraging functional outcomes.
- A regulatory decision is expected on January 21, 2027.
If approved, z-rostudirsen could become another treatment option for individuals with Duchenne muscular dystrophy amenable to exon 51 skipping, further expanding the therapeutic landscape for this devastating genetic disease.
Follow This Page >>> All Clinical Trials for Duchenne
